Actualités

CVS Health has outpaced the S&P 500 Index over the past year, and analysts are highly optimistic about the stock’s prospects.

Smart beta had a confusing first half of 2026, as momentum cooled after a strong 2025, low-volatility lagged a market that kept grinding higher, and dividend growth funds got squeezed by another leg up in yields. The strategies that held their ground share a common screen: companies that generate real cash and earn returns above ... Three Free Cash Flow and Quality ETFs Quietly Beating Every Other Smart Beta Strategy in 2026

Eli Lilly and Company just secured a big win as it looks to expand GLP-1 access, mending its partnership with top pharmacy benefit manager CVS Health.

AbbVie, CVS Health, and Verizon Communications are all high-yielding stocks with attractive valuations and robust financials.

These aren't the most exciting businesses, but they have a lot to offer to long-term investors.

Growth, not yield, is the deciding factor.

CVS Health (CVS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Salesforce (NYSE:CRM) expanded its Agentforce Health partnership with CVS Health, described as its largest Agentforce agreement in regulated industries. The company launched a Forward Deployed Engineering partner network with TTEC Digital to support AI agent deployments. Salesforce also extended AI powered customer engagement capabilities across several sectors, including healthcare and other regulated markets. Salesforce, trading at $191.1, has seen mixed share performance, with the stock...

CVS Health (NYSE:CVS) received the 2026 Newsweek AI Impact Award for its AI-driven prescription technology. The company was recognized for AI tools that standardize prescription inputs and support safer medication dispensing across its pharmacy network. CVS Health Ventures made a major investment in healthcare AI startup H1 to improve provider data accuracy. For a company that operates a large US pharmacy and health services network, CVS Health’s latest AI moves relate directly to its core...

CVS Caremark has granted preferred formulary status to both Novo Nordisk's Wegovy and Eli Lilly's Zepbound and Foundayo. This decision reverses Wegovy's prior commercial advantage within CVS Caremark's GLP-1 obesity drug coverage. The change affects access and competitive positioning for GLP-1 obesity therapies in CVS Caremark's network. Novo Nordisk, listed as CPSE:NOVO B, is a key player in GLP-1 based therapies, with Wegovy at the center of its obesity drug portfolio. CVS Caremark's move...

Large-cap stocks usually command their industries because they have the scale to drive market trends. The flip side though is that their sheer size can limit growth as expanding further becomes an increasingly challenging task.

CVS restores broader Zepbound coverage after price cuts, putting Wegovy and Zepbound on equal footing.

CVS Health (NYSE:CVS) has launched Aetna Mental Health On Demand to widen access to virtual behavioral health services. The company is expanding its pharmacy benefits with updated GLP-1 formulary options for weight loss medications. CVS Health has broadened its AI-focused collaboration with Salesforce to support members and providers through more tailored digital tools. For investors watching NYSE:CVS, these moves sit at the intersection of managed care, retail pharmacy, and digital health...

Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3.4% in the afternoon session after CVS restored Zepbound as a co-preferred option and simultaneously added Lilly's new oral obesity pill Foundayo, making Eli Lilly's full obesity medication portfolio accessible to all three of America's largest pharmacy benefit managers for the first time.

CVS Health Corporation (NYSE:CVS) is one of the 12 Strong Buy Stocks to Buy and Hold for the Next 5 Years. On May 21, 2026, Glenview Capital said CVS Health Corporation (NYSE:CVS) remains one of its three largest positions after a partial rebalance. Glenview said CVS shares have generated a total return of 80% since […]

The change could improve patient access and support future sales growth.

The move gives patients broader access to Lilly's obesity drugs and strengthens competition with Novo Nordisk.

Eli Lilly shares are on pace to hit a new all-time closing high on news of increased insurance coverage for its blockbuster weight-loss drug Zepbound. Lilly shares were recently up 4.4% to $1,130.90. Pharmacy-benefit manager CVS Caremark decided to add back Lilly’s Zepbound weight-loss drug to its lists of preferred drugs.

Investors shouldn't lose sleep over the possibility that the dividend is in danger.

Today, May 28, 2026, investors piled into Snowflake after its Amazon pact and earnings beat, even as the Dow barely budged.

CEO Ariel Katz argues that while AI can replicate workflow SaaS, it can't copy H1’s unique doctor data.

CVS Health will reinstate coverage of Eli Lilly's weight-loss injectable Zepbound and begin coverage of the anti-obesity pill Foundayo.

CVS Health’s decision to expand formulary coverage for key GLP-1 therapies marks a boost for Eli Lilly's obesity drug business.

CVS Health’s Caremark will resume insurance coverage of Eli Lilly’s Zepbound and separately begin covering its Foundayo weight-loss pill.

The S&P 500 and Nasdaq Composite were up, while the Dow Jones Industrial Average was down slightly i

Eli Lilly and Company (NYSE:LLY) shares gained about 1% in premarket trading Thursday after CVS Caremark announced it would add the company’s obesity treatment Zepbound to its preferred drug formulary. Lilly said the decision means all three of the largest pharmacy benefit managers in the United States will now provide coverage for the company’s full obesity medicine portfolio.

The pharmacy benefit manager dropped Zepbound a year ago in favor of rival Wegovy — now both Lilly and Novo Nordisk drugs will be co-preferred options

The agreement includes Lilly’s new pill Foundayo and restores coverage for Zepbound, erasing what had been a commercial edge for rival Novo Nordisk.

May 28 () - CVS Health said on Thursday it will add Eli Lilly's weight-loss drug Zepbound back to some ‌of its drug lists as an additional preferred option ‌for insurance coverage. Caremark, CVS' pharmacy benefit management unit, had dropped Zepbound from coverage ​on July 1 last year, while continuing to reimburse for rival Novo Nordisk's Wegovy after negotiating a more favorable price from the Danish drugmaker.

Eva Boratto, who spent more than a decade at CVS in a variety of finance roles, will join the drug distributor later this summer, Cencora announced Wednesday.